A synbiotic formula (SIM01) developed by Hong Kong firm GenieBiome in collaboration with the Chinese University of Hong Kong has been shown to alleviate multiple symptoms of post-acute COVID-19 syndrome (PACS), while also benefiting children after their COVID-19 vaccination.
Summary
A new study is currently enrolling people with long COVID who have not yet been vaccinated. The work could tell researchers what’s driving the condition and offer clues to treatment.
Within the last few months, some people with lingering COVID-19 symptoms have been reporting something surprising: vaccination seems to improve their condition. These patients, known as “long haulers” or people with “long COVID,” suffer from a host of full-body symptoms that can make it difficult to walk, concentrate, and breathe.
Now, scientists have launched a new study to examine just how vaccination affects these individuals, and whether the vaccine can offer clues to treatment. Researchers are currently recruiting people over 18 who have not yet been vaccinated and have had COVID-19 symptoms for more than two months since their initial infection, announced study leader Akiko Iwasaki, a Howard Hughes Medical Institute Investigator at Yale University.